Current status and challenges in the next steps for TAVR in China

Samir R. Kapadia1*, MD; Toshiaki Isogai2, MD, MPH

1. Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA; 2. Department of Cardiology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan

Transcatheter aortic valve replacement (TAVR) has been established as standard interventional therapy for symptomatic severe aortic stenosis (AS) regardless of surgical risk owing to multiple pivotal trials along with technological advances and increased procedural experience. This evolution in interventional cardiology has led to huge expansions of TAVR into clinical practice in Western countries. In Asian countries, although the initial uptake of this intervention lagged behind Western countries, more recently, its adoption has been rapidly and widely spreading. Nationwide registry data in Japan have demonstrated that the safety and effectiveness of TAVR have been comparable to those in Western countries. Meanwhile, reports from China have been mainly limited to small studies so far. Considering the population size and the ageing society in China, AS represents an increasing healthcare and socioeconomic burden, warranting a better understanding of the current status of TAVR in China.

In the current issue of AsiaIntervention, Wei et al have reported a systematic review regarding the characteristics and outcomes of TAVR in China. To our knowledge, this is the first systematic review of literature for TAVR recipients in China. The main findings are the following: (i) in China, although surgical aortic valve replacement remains the most common therapeutic option (~40,000 procedures per year) for severe AS, TAVR has been increasingly performed over recent years (from 293 procedures in 2017 to 7,357 procedures in 2021); (ii) bicuspid morphology is common (up to ~50%) as an aetiology for severe AS in patients undergoing aortic valve replacement in China, posing clinical challenges for TAVR; (iii) four locally manufactured self-expanding transcatheter heart valves (THVs) and the balloon-expandable SAPIEN 3 THV (Edwards Lifesciences) are available for use in China, although large-scale data regarding their safety and effectiveness are still lacking; and (iv) it seems that TAVR can be performed safely in the Chinese population, nonetheless, warranting further studies. This systematic review summarises the currently available data and provides insights into the challenges for the next steps in the field of TAVR in China. The authors are to be congratulated on their contributions to this topic in Asia.
in China appeared comparable to those in Western countries\textsuperscript{1-3} and Japan\textsuperscript{4}, despite a higher prevalence of bicuspid morphology in Chinese candidates. However, given the small sample sizes of the included studies (Chinese domestic THVs, n=25 to 238; SAPIEN 3, n=50 to 438) and potential reporting biases in this systematic review, the generalisability of the currently available data may be limited. To address this issue, it is important to establish a high-quality nationwide registry that contains detailed clinical information, like the Society of Thoracic Surgeons-American College of Cardiology Transcatheter Valve Therapy (STS-ACC TVT) Registry in the USA\textsuperscript{4}.

Indeed, in China, there is a national registry named the National Transcatheter Valve Therapeutics Registry (NTCVR)\textsuperscript{5}, in which 83 heart valve centres had participated up until April 2022, with a total of 4,787 cases of aortic valve procedures nationwide. However, a previous report mentioned that most centres had not submitted data to the NTCVR database\textsuperscript{6}. One possible solution for the low data submission is that submission of data is made mandatory for reimbursement of the procedure, as is the case with the STS-ACC TVT Registry. High-quality real-world data with follow-up will help to understand the updated status of TAVR in China and produce novel evidence. As differences exist between Asian and Western patients in terms of body size and aortic valve complex, such clinical data in China are useful to address whether the evidence from Western patients is applicable to Asian patients.

A unique feature of TAVR in China is the availability of four locally developed self-expanding THVs that have received Chinese regulatory approval: the Venus A-Valve (Venus Medtech), J-Valve (JieCheng Medical), VitaFlow Aortic Valve (MicroPort), and TaurusOne (Peijia Medical). Although the review by Wei et al revealed that the need for second valve implantation was remarkably high (>10%) in TAVR with Chinese domestic devices, the early data seemed to support acceptable safety. However, there is no randomised trial supporting the safety and effectiveness of these domestic THVs in China, similar to the situation in India, where indigenous THVs are also available\textsuperscript{7}. Recently, a randomised head-to-head international trial demonstrated that the balloon-expandable Myval (Meril Life Sciences) was non-inferior to the SAPIEN and Evolut (Medtronic) series in terms of the primary composite endpoint at 30 days\textsuperscript{8}. These results provide reassurance concerning the periprocedural safety of Myval, and longer-term outcomes are awaited. In a similar manner, randomised trials are required to establish the evidence on the safety and effectiveness of Chinese domestic THVs compared with existing THVs.

The current evidence supports that the outcomes of TAVR (as well as other evolving structural heart interventions) largely depend on device technology and procedural experience\textsuperscript{9}. In this context, it is essential to accumulate data about the characteristics and outcomes of TAVR in each country/area to confirm the safety and effectiveness achieved in other areas in the world. Learnings from the accumulated data can be extrapolated to other countries, such as India, South American countries, etc. There are remaining issues with TAVR for Chinese patients: optimal antithrombotic regimen, risk of patient-prosthesis mismatch, the feasibility of redo-TAVR (i.e., TAVR-in-TAVR), and long-term durability of THVs, particularly in patients with a small aortic valve complex. We hope that China will take further steps to address these issues in the field of TAVR in Asia.

Conflict of interest statement

The authors have no conflicts of interest to declare.

References


